# ELI LILLY AND COMPANY (LLY) · Edgar & Edgarette company card

> Eli Lilly And Company (LLY) grew revenue 44.7% in FY2025 to $65.2 billion, equity 23.6% of assets, and dividend per share up 10 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 59478 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/LLY) · [JSON](https://www.pops4.com/boards/company/LLY.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $65.2B |
| Revenue growth, 1 year | 44.7% |
| Revenue growth per year | 23.2% |
| Operating margin | — |
| Net margin | 31.7% |
| Operating cash flow | $16.8B |
| Capital spending | — |
| Free cash flow | — |
| Cash | $7.3B |
| Long-term debt | $42.5B |
| Total assets | $112.5B |
| Total equity | $26.5B |
| Equity ÷ assets | 23.6% |
| Return on equity | 77.8% |
| Dividend per share | $6.23 |
| Dividend years rising | 10 |

## Readings, computed from those figures

- Piotroski F: 7 of 9 (solid)
- Beneish M: -1.85 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $65.2B (FY2025), total debt $42.5B. Experience: revenue up 44.7% on the year, up 23.2% a year over 4 years. Soundness: equity 23.6% of assets, return on equity 77.8%, payout 26.1% of profit, dividend per share up 10 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $73.8B and $102.1B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $64.0B to $116.2B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): growth 44.7% against 13.7%.

Range logged 2026-09-26, receipt a3003adc099f518a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2025-11-21 ([filing](https://www.sec.gov/Archives/edgar/data/59478/000005947825000271/0000059478-25-000271-index.htm))

## Recent filings

- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/0000059478-26-000104-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/0000059478-26-000077-index.htm)
- 8-K · filed 2026-05-20 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/59478/000119312526232707/0001193125-26-232707-index.htm)
- 8-K · filed 2026-05-07 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/59478/000005947826000048/0000059478-26-000048-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000059478.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=59478

## Cite

POPS4, Edgar & Edgarette: ELI LILLY AND COMPANY (LLY) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/LLY. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.